caa a22 4500 445882875 CHVBK 20180317145549.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10157-011-0485-2 doi (NATIONALLICENCE)springer-10.1007/s10157-011-0485-2 Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients [Elektronische Daten] [Shunji Shiohira, Takumi Yoshida, Hidekazu Sugiura, Satsuki Yoshida, Michihiro Mitobe, Katsunori Shimada, Takashi Ohba, Ken Tsuchiya, Takashi Kabaya, Kosaku Nitta] Background: Peripheral artery disease (PAD) is a common complication in patients receiving hemodialysis (HD). Cilostazol is used for the treatment of ischemic symptoms in patients with PAD, based on its antiplatelet and vasodilating effects. In addition to these beneficial effects on clinical symptoms in PAD patients, cilostazol has been proposed to have additional effects on clinical symptoms in patients with restless legs syndrome (RLS) via the upregulation of dopamine. We performed an observational, prospective study to evaluate the effect of cilostazol on several clinical and biochemical parameters in HD patients with PAD and RLS. Methods: All the study patients received cilostazol treatment for 12months. During the study period, several biochemical parameters, such as high-sensitivity CRP, von Willebrand antigen (VW-Ag), triglyceride (TG), high-density lipoprotein (HDL) and malondialdehyde-modified low-density lipoprotein, were monitored. A questionnaire on the physical status of PAD and RLS was also completed. 45 HD patients who received cilostazol were compared with a control group of 22 patients. Results: The patients who continued cilostazol treatment exhibited a improvement in their serum inflammatory and biochemical parameters (VW-Ag, TG, HDL). Although PAD and RLS scores were not improved by multivariate analysis, several patients showed improvement of signs and symptoms which were included in the PAD or RLS scores. Conclusion: The treatment of HD patients with cilostazol improved some of the lipid-related and endovascular inflammatory biochemical parameters associated with PAD, and relieved the clinical symptoms and physical status of PAD in some cases. Japanese Society of Nephrology, 2011 Cilostazol nationallicence Peripheral artery disease nationallicence Restless legs syndrome nationallicence Shiohira Shunji Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Yoshida Takumi Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Sugiura Hidekazu Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Yoshida Satsuki Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Mitobe Michihiro Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Shimada Katsunori STATZ Institute Inc., Shinjuku, Tokyo, Japan aut Ohba Takashi Department of Blood Purification, Minamisenju Hospital, Arakawa, Tokyo, Japan aut Tsuchiya Ken Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Kabaya Takashi Department of Blood Purification, Minamisenju Hospital, Arakawa, Tokyo, Japan aut Nitta Kosaku Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut Clinical and Experimental Nephrology Springer Japan 15/6(2011-12-01), 893-899 1342-1751 15:6<893 2011 15 10157 https://doi.org/10.1007/s10157-011-0485-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-011-0485-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Shiohira Shunji Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Yoshida Takumi Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Sugiura Hidekazu Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Yoshida Satsuki Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Mitobe Michihiro Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Shimada Katsunori STATZ Institute Inc., Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Ohba Takashi Department of Blood Purification, Minamisenju Hospital, Arakawa, Tokyo, Japan aut NATIONALLICENCE 700 1- Tsuchiya Ken Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 700 1- Kabaya Takashi Department of Blood Purification, Minamisenju Hospital, Arakawa, Tokyo, Japan aut NATIONALLICENCE 700 1- Nitta Kosaku Department of Medicine IV, Tokyo Women's Medical University, 8-1 Kawada-cho, 162-8666, Shinjuku, Tokyo, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/6(2011-12-01), 893-899 1342-1751 15:6<893 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer